MiNK Therapeutics Reports Third Quarter 2026 Results and First Pre-Commercial Product Revenue
MiNK Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, recognizing its first pre-commercial product revenue of $0.2 million from its lead candidate, agenT-797. This revenue was generated through its international named-patient acces